Abstract

With the emergence of new endocrine drugs and the development of research in resistance mechanisms, significant progress has been achieved in the endocrine treatment of breast cancer in recent years. Fulvestrant, the combination of endocrine drugs and the combination of targeted therapy with endocrine therapy will be effective treatments for postmenopausal women with hormone receptor positive in advanced breast cancer. Key words: Breast neoplasms; Receptors, estrogen; Therapy

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.